Financial Highlights

财务亮点

Revenue reached RMB1,729.4 million

收入达到人民币17.294亿元

Gross profit amounted to RMB655.6 million

毛利润达到人民币6.556亿元

Gross profit margin recorded 37.9%, a YOY increase of 3.3 pp

毛利率为37.9%，同比增长3.3个百分点。

Net profit recorded RMB269.3 million, a YOY increase 21.3%

净利润录得人民币2.693亿元，同比增长21.3%

Adjusted non-IFRS net profit recorded RMB335.3 million, a YOY increase of nearly 6.6%

调整后的非国际财务报告准则净利润为人民币3.353亿元，同比增长近6.6%。

SHANGHAI

上海

,

，

March 30, 2026

2026年3月30日

/PRNewswire/ -- On March 30, 2026, Viva Biotech Holdings ('Viva Biotech', 'the Group' or 'the Company', stock code: 1873.HK) announced that for the Group's revenue amounted to RMB1,729.4 million during the Reporting Period, with gross profit of RMB655.6 million. The Group's gross profit margin was 37.9%, representing an increase of 3.3 percentage points compared with the same period last year, mainly attributable to the optimization and adjustment of Langhua Pharmaceutical's business mix, improved operational efficiency of the CRO business.

/PRNewswire/ -- 2026年3月30日，维亚生物科技控股集团（“维亚生物”，“集团”或“公司”，股票代码：1873.HK）宣布，报告期内集团收入达人民币17.294亿元，毛利为人民币6.556亿元。集团毛利率为37.9%，较去年同期增长3.3个百分点，主要得益于朗华制药业务结构的优化与调整以及CRO业务运营效率的提升。

Throughout 2025, the Group's net profit was RMB269.3 million, representing a year-on-year increase of 21.3% compared with RMB220.0 million in the same period last year. Adjusted non-IFRS net profit increased from RMB314.6 million in the same period last year to RMB335.3 million, representing a year-on-year increase of approximately 6.6%, which was mainly due to the revenue growth of the CRO business, improved profitability arising from the optimization of Langhua Pharmaceutical's business mix, as well as investment income from the successful exit from incubation portfolio companies..

整个2025年，集团净利润为2.693亿元人民币，相比去年同期间的2.2亿元人民币，同比增长21.3%。调整后的非国际财务报告准则净利润从去年同期的3.146亿元人民币增加到3.353亿元人民币，同比增长约6.6%，这主要得益于CRO业务的收入增长、朗华制药业务组合优化带来的盈利能力提升，以及成功退出孵化投资组合公司所带来的投资收益。

CRO Business Sustained Recovery in Growth, AI-Enabled Drug Discovery Technology Maintained Industry-Leading Advantages

CRO业务持续复苏增长，AI赋能药物发现技术保持行业领先优势

Throughout 2025, revenue from the Company's CRO business rose from RMB810.9 million in the same period last year to RMB848.6 million, representing a growth of approximately 4.7%. Corresponding adjusted gross profit increased from RMB357.1 million in the same period last year to RMB383.1 million, an increase of approximately 7.3%.

2025年全年，公司CRO业务收入从去年同期的8.109亿元增长至8.486亿元，增幅约为4.7%。相应的调整后毛利润从去年同期的3.571亿元增长至3.831亿元，增幅约为7.3%。

The total number of CRO clients of the Company increased to 1,866, including the World's top Ten pharmaceutical companies, revenue from the top ten clients accounted for 25.7% of our total revenue..

公司CRO客户总数增加到1866家，其中包括世界十大制药公司，前十大客户收入占我们总收入的25.7%。

As of December 31, 2025, the Company had delivered more than 98,885 protein structures to clients, among which approximately 16,169 structures were newly delivered in 2025. Research covered more than 2,345 independent drug targets, with 247 new targets delivered. The utilization of synchrotron radiation sources totaled 1,673 hours during 2025.

截至2025年12月31日，公司已向客户交付超过98,885个蛋白质结构，其中约16,169个结构为2025年新交付。研究覆盖了超过2,345个独立药物靶点，新增交付247个新靶点。2025年同步辐射光源的使用总时长达到1,673小时。

Revenue from novel molecular modalities (including peptides, antibodies, XDCs, PROTAC/molecular glues, etc.) accounted for approximately 15.8% of total CRO revenue, representing a year-on-year increase of nearly 11.0%. It is evident that novel molecular modalities are gradually emerging as a new growth driver for CRO revenue..

新型分子模式（包括多肽、抗体、XDC、PROTAC/分子胶等）的收入约占CRO总收入的15.8%，同比增长近11.0%。可见，新型分子模式正逐渐成为CRO收入新的增长驱动力。

The Company has continuously strengthened the deployment of new platforms and raised the technical barriers of core platforms, and secured integrated one-stop service contracts through the synergistic development of biology and chemistry. In addition, for the AI in drug research and development, the combination of dry and wet laboratories has driven continuous growth.

公司持续强化新平台的布局，提高核心平台的技术壁垒，通过生物和化学协同发展的模式获得整合的一站式服务合同。此外，在药物研发人工智能方面，干湿实验室结合驱动持续增长。

As of December 31, 2025, the total number of projects supported by AIDD reached 196, and the number of clients purchasing CADD/AIDD services amounted to 73. Revenue from AI-enabled projects accounted for approximately 12.0% of total CRO revenue. The Company's AI capabilities cover the entire workflow of First-in-Class drug discovery, focusing on new targets, novel mechanisms of action (MOA), and new modality..

截至2025年12月31日，AIDD支持的项目总数达到196个，购买CADD/AIDD服务的客户数量达73个。人工智能赋能项目的收入约占CRO总收入的12.0%。公司的AI能力覆盖了首创药物发现的整个工作流程，聚焦于新靶点、新作用机制（MOA）和新模态。

Successful Commercial Launch of New CDMO Projects, Sustained Improvement in CMC Business Profitability

新CDMO项目成功实现商业化投产，CMC业务盈利能力持续提升

The Group is committed to building a global one-stop service platform covering the entire innovative drug value chain from R&D to manufacturing. Through acquisition of the entire equity interests in Zhejiang Langhua Pharmaceutical Co., Ltd. ('Langhua Pharmaceutical'), the Group has further strengthened its manufacturing footprint.

该集团致力于打造一个覆盖从研发到生产整个创新药物价值链的全球一站式服务平台。通过收购浙江朗华制药有限公司（“朗华制药”）的全部股权，该集团进一步增强了其生产能力。

During the Reporting Period, two new CDMO commercial projects were successfully launched, one project is approaching commercial production and delivery, while the other has commenced PPQ manufacturing. These two projects are expected to be commercially launched in 2026 and 2027 respectively, and will become new growth drivers for the CDMO business in the future..

报告期内，成功落地两项新的CDMO商业化项目，其中一个项目已临近商业化生产和交付，另一个项目已进入PPQ生产阶段。该两个项目预计会分别于2026年及2027年实现商业化，未来将成为CDMO业务新的增长动力。

Meanwhile, the CMC business has achieved higher project delivery rates through the optimization of customer structure. The continuous introduction of overseas clients and incubation portfolio companies has driven gross margin improvement and successfully reduced losses. CMC has completed or is advancing a total of 295 new drug projects, with a research and development team of 96 professionals.

同时，CMC业务通过优化客户结构，实现了更高的项目交付率。海外客户的持续引入和孵化组合公司的增加推动了毛利率的提升，并成功减少了亏损。CMC已完成或正在推进总计295个新药项目，拥有96名专业人员的研发团队。

In terms of customer order volume, internal referrals from Viva contributed around 55.0%, and in terms of customer value, internal referrals accounted for 72.0%..

在客户订单量方面，Viva的内部推荐贡献了约55.0%，而在客户价值方面，内部推荐占72.0%。

Throughout 2025, Langhua Pharmaceutical recorded total revenue of RMB880.8 million and adjusted gross profit of RMB286.6 million, served a total of 920 clients. Revenue from its Top Ten clients accounted for 68.0% of total revenue, with a 100.0% retention rate for the top ten clients. The total available production capacity is 860 cubic meters, which is sufficient to support the actual production needs over the next two years.

2025年全年，朗华制药录得总收入8.808亿元人民币，调整后毛利润2.866亿元人民币，共服务客户920家。来自前十大客户的收入占总收入的68.0%，前十大客户保持率为100.0%。总可用产能为860立方米，足以支持未来两年的实际生产需求。

In addition, Langhua Pharmaceutical is constructing an additional 400 cubic meters of capacity to support the scaled-up production demand in the future..

此外，朗华制药正在建设额外400立方米的产能，以支持未来规模化生产的需求。

Multiple Incubation Portfolio Companies Realized Exit Gains

多家孵化投资企业实现退出收益

During the Reporting Period, the Company realized corresponding investment income through exits from multiple incubation portfolio companies, with cumulative repayments of nearly RMB83.6 million. As of December 31, 2025, the Company had invested in and incubated a total of 93 start-ups. 13 of the Company's incubation portfolio companies had completed or were close to completing a new round of financing, with aggregate financing amounting to approximately US$453.3 million.

在报告期内，公司通过退出多个孵化组合公司实现了相应的投资收益，累计回款近8360万元。截至2025年12月31日，公司已投资孵化初创企业共计93家，其中13家孵化组合公司已完成或接近完成新一轮融资，合计融资额约4.533亿美元。

All incubation portfolio companies have made smooth progress in R&D, with a total of nearly 231 pipelines under research, of which 187 pipelines are at the pre-clinical stage and 44 are at the clinical stage. To date, full or partial exits have been achieved for 19 incubated projects..

所有孵化组合公司研发进展顺利，共有近231条管线在研，其中临床前阶段187条，临床阶段44条。截至目前，已有19个孵化项目实现全部或部分退出。

Staff and Facilities

员工与设施

As at December 31, 2025, the Group had a total of 2,169 employees, of whom the number of CRO R&D personnel reached 1,123, and the headcount of Langhua Pharmaceutical was 787. The Company has well-established office and laboratory facilities in line with its workforce expansion plans, and is expanding production capacity to meet the fast-growing business needs..

截至2025年12月31日，集团共有员工2,169人，其中CRO研发人员达1,123人，朗华制药员工数为787人。公司根据其人力扩展计划，已建立完善的办公和实验室设施，并正在扩大生产能力以满足快速增长的业务需求。

Logo -

标志 -

https://mma.prnewswire.com/media/2934554/Viva_Logo.jpg

https://mma.prnewswire.com/media/2934554/Viva_Logo.jpg

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示